Rate My Professor Oliver Eltherington

Oliver Eltherington served at the University of Otago from 2019 to 2023 in key technical roles within the Health Sciences Division. He began as an Assistant Research Fellow in the Department of Pathology, Dunedin School of Medicine, from September 2019 to January 2021. From January 2021 to March 2023, he worked as a Research Technician in the Department of Microbiology and Immunology, managing the flow cytometry core facility at Otago Micro and Nanoscale Imaging (OMNI). Responsibilities included user training, equipment maintenance, customer service, and instruction on safe handling of viral vectors. His contributions supported numerous research projects through advanced flow cytometry services, earning acknowledgments in multiple postgraduate theses for assistance with FACS analyses and imaging.

Eltherington's academic background comprises studies in Biology at the University of Stirling (2010-2014), Immunology at Newcastle University (2014-2015), and a Master of Research degree from the University of Melbourne. His expertise spans flow cytometry, cell culture, Western blot analysis, autoimmunity, inflammation, transfection, cell proliferation, DNA extraction, tissue culture, and human cell culture. Research specializations center on immunology, immunotherapy, dendritic cells, and related biomedical applications. Notable publications include co-authorship on "The Mouse Papillomavirus Epigenetic Signature Is Characterised by DNA Hypermethylation after Lesion Regression" (Viruses, 2021), investigating epigenetic changes in papillomavirus lesions. From prior work at Newcastle University, he contributed to "Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis" (Annals of the Rheumatic Diseases, 2017), "Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-β1" (Clinical & Experimental Immunology, 2017), and "Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis" (Journal of Translational Medicine, 2019). These works demonstrate his impact in advancing understanding of tolerogenic dendritic cells for arthritis treatment. Eltherington's technical proficiency has bolstered research in pathology, molecular medicine, and immunology at Otago.